Merck’s HIV pipeline shifts as PrEP program discontinues
Pharmaceutical Technology
OCTOBER 1, 2022
Last week, Merck & Co announced it is discontinuing a program to study monthly oral doses of islatravir as pre-exposure prophylaxis (PrEP) therapy. This news came after the pharma giant halted islatravir studies for the prevention and treatment of HIV infections in December 2021 on grounds of safety.
72 
Let's personalize your content